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ABSTRACT 
Chemotherapy has represented the standard therapy for unresectable or metastatic urothelial 
carcinoma for more than 20 years. The growing knowledge of the interaction between tumour and 
immune system has led to the advent of new classes of drugs, the immune-checkpoints inhibitors, 
which are intended to change the current scenario.  
To date, immunotherapy is able to improve the overall responses and survival. Moreover, thanks to 
its safety profile immune-checkpoint inhibitors could be proposed also to patients unfit for standard 
chemotherapy. 
No doubts that these agents have started a revolution expected for years, but despite this 
encouraging results it appears clear that not all subjects respond to these agents and requiring the 
development of reliable predictive response factors able to isolate patients who can more benefit 
from these treatments as well as new strategies aimed to improve immunotherapy clinical outcome. 
In this review we describe the active or ongoing clinical trials involving Programmed Death Ligand 
1 (PD-L1), Programmed Death receptor 1 (PD-1) and Cytotoxic-T Lymphocyte Antigen 4 (CTLA 
4) inhibitors in urothelial carcinoma focusing our attention on the developing new immune-agents 
and combination strategies with immune-checkpoint inhibitors.    
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1. INTRODUCTION 
Urothelial cancer of the bladder, renal pelvis, ureter and other urinary organs is the most common 
malignancy involving the urinary system and the ninth most common malignancy worldwide, with 
about 430000 new cases diagnosed in 2012 [1]. 
           In metastatic or unresectable disease, Cisplatin combination regimens have represented the standard 
First line therapy for patients with good performance status while patients unfit to Cisplatin were 
generally treated with Carboplatin regimens or platinum-free combinations containing taxanes and 
gemcitabine with an Overall Survival (OS) benefit achieved of 14 months [2-5].  
After progression to first line several drugs have been tested without significant improvement in 
mOS except for Vinfluine, which showed an OS benefit only in eligible patients population 
compared to best supportive care in a phase III trial [6,7].  
From more than 20 years no active treatments have shown to improve clinical outcome of patients 
with UC compared to chemotherapy. This until the demonstration that bladder cancer, like 
melanoma and non small cell lung cancer, is a tumour with a high somatic mutation frequencies and 
a high antigenic expression resulting in an optimal target for immune-checkpoint inhibitors [8].  
PD-1 and PD-L1 are members of the Ig superfamily expressed on hematopoietic and non-
hematopoietic cells (PD-L1) as well as on T Cell surface (PD-1). PD-L1/PD-1 interaction leads to 
‘’T-Cell exhaustion’’ that consisted of impaired cytotoxic activity and decreased effector cytokine 
production resulting in immune-response inhibition. 
Atezolizumab (MPDL3280A) is an engineered, humanised monoclonal IgG1 antibody, with a high 
affinity for PD-L1 acting as inhibitor of the interaction between PD-L1 and PD1/B7.1. It was the 
First immune agents who showed clinical activity in UC [9]. On the wave of the positive results 
obtained in phase I trial, a following phase II trial (IMvigor 210 trial, NCT02108652) with two 
different cohorts was performed (cohort 1, patients with metastatic urothelial cancers ineligible for 
platinum based chemotherapy for First line treatment; cohort 2, patients who progressed during or 
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following platinum-based treatment). Regarding, Cohort 2 (n=310), patients who received 
Atezolizumab showed an Objective Response Rate (ORR) of 15% and a 12-month OS of 37% in 
the overall population with a median duration of response not reached after a medium of 
17.5 months of follow-up [10].  
Results of Cohort 1 (n=119) showed an ORR of 23% in the whole cohort with a median duration of 
response not reached at 14.4 months of follow-up and a median OS of 14.8 months (95% CI 10.1 
months to not reached) [11]. 
On the basis of the favourable results of the cohort 2, Atezolizumab has been approved by FDA for 
the treatment of patients with locally advanced or metastatic UC who have progressed during or 
following platinum-based chemotherapy or whose disease has worsened within 12 months 
neoadjuvant or adjuvant platinum-based chemotherapy.   
Despite these remarkable results, more recently Powees et al recently presented preliminary results 
of IMvigor211. This was a randomized phase III trial of Atezolizumab compared to chemotherapy 
(docetaxel, paclitaxel and vinflunine) in patients progressed to platinum based therapy. Surprisingly 
Atezolizumab failed to show an improvement in Overall Survival in overall population (8.6 vs 8.0 
months for Atezolizumab and chemotherapy respectively, HR 0.85) and in patients with high PD-
L1 expression (11.6 vs 10.6 months, HR 0.87) [12].  
Pembrolizumab (MK-3475) is a humanized monoclonal IgG4 antibody against PD-1, which 
showed to be a safety and active treatment in a phase I basket trial involving also patients with UC 
[13]. Thanks to the positive results obtained in this study Pembrolizumab has been compared to 
standard second line chemotherapy in a large phase III clinical trial (Keynote 045) [14]. In this 
study 542 patients with locally advanced or metastatic predominantly transitional UC, progressed to 
First line platinum regimens or with recurrence disease within 12 months after adjuvant or 
neoadjuvant platinum containing therapy, were randomized (1:1) to receive Pembrolizumab 200 mg 
every 3 weeks (Q3W) or chemotherapy (paclitaxel 175 mg/m2 Q3W or docetaxel 75 mg Q3W or 
Vinfluine 320 mg/m2 Q3W). Results of this study showed a better OS for patients treated with 
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Pembrolizumab in overall population (mOS 10.3 vs 7.4 months HR 0.73, 95% CI, 0.59 – 0.91, p= 
0.002) and in patients with high PD-L1 expression (mOS 8.0 vs 5.2 months HR 0.57, 95% CI, 0.37-
0.88, p = 0.0048). No differences in terms of PFS have been found between the two arms. ORR as 
assessed on the intention to treat population) was significantly better in Pembrolizumab arm (21.1 
% vs 11.4 %) with a duration of response not reached (1.6 – 15.6+ months).  
Partial results of the still ongoing phase II KEYNOTE 052 trial seems to confirm this positive 
results also when Pembrolizumab is adopted as First line therapy in platinum unfit patients with UC 
[15].  
Nivolumab (MDX 1106) is a fully human IgG4 monoclonal antibody against PD-1 that has been 
approved for treatment of advanced melanoma, Hodgkin lymphoma, non-small cell lung cancer, 
head and neck cancer, and renal cell cancer. In UC it showed to be an active and safety treatment in 
phase I and II studies [16,17]. As observed with Nivolumab also the PD-L1 inhibitors Avelumab 
(MSB0010718C) and Durvalumab (MEDI4736) showed promising activity in phase I/II clinical 
trials in patients with UC suggesting the development of further clinical trials exploring these 
agents in different setting of UC [18-21]. The CTLA-4 receptor also known as CD156 is a member 
of the immunoglobulin superfamily and a transmembrane receptor expressed exclusively on T cells. 
The activation of CTLA-4 happened through interaction with CD80 and CD86 on antigen 
presenting cells and leads to a down-regulation of T helper lymphocyte and enhanced regulatory T 
cell immunosuppressive activity resulting in immune response inhibitor signal [22].  
Ipilimumab is a CTLA-4 inhibitor that showed in a small clinical trial to be a safety preoperative 
treatment in patients with bladder UC [23].  
On the basis of the positive outcome obtained it seems clear that the treatment paradigm of UC is 
about to change. The demonstration that immunotherapy could led to long term responses in 
different setting of UC and the safety profile showed in different clinical trials have move the 
development of several studies exploring these agents. This has led to in a complex scenario that 
will profoundly change the management of the disease. In the next paragraphs we will describe the 
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ongoing and active clinical trials exploring these agents in different setting of the disease. In table 1 
and table are summarized the phase III and phase I, I/II, II descripted in this manuscript.  
 
2. PD-1 AND PD-L1 INHIBITORS 
On the wave of the positive outcome obtained previously descripted clinical trials PD-1 inhibitors: 
Pembrolizumab and Nivolumab as well as the PD-L1 inhibitors: Atezolizumab, Avelumab and 
Durvalumab are being tested individually in different clinical trials and in different stages of the 
disease. 
Regarding preoperative setting Pembrolizumab is being tested in a phase II trial enrolling 90 
patients with muscle invasive bladder UC (T2-T4 N0) with residual disease after transurethral 
resection (NCT02736266). Patients enrolled will receive 3 cycles of Pembrolizumab (200 mg 
Q3W) before planned cystectomy with primary endpoint: pathological complete response rate. 
Another phase II trial is currently exploring the role of Atezolizumab as preoperative treatment in 
patients with T2-T4a urothelial bladder cancer (NCT02662309). Of note primary endpoints of this 
studies are the pathological complete response rate (pCRR, defined as ≥20% reduction in residual 
disease of the bladder based on histological evaluation of the resected bladder specimen collected 
during cystectomy post-treatment) and the dynamic changes in T cell subpopulations (CD8 and/or 
CD3) measured in tumour samples collected pre- and post-treatment. 
Immune-checkpoint inhibitors are also under investigation in early stage of the disease. Indeed, a 
phase II trial (NCT02625961) will test Pembrolizumab in 260 patients with high risk non muscle 
invasive bladder cancer (high risk Ta, T1, carcinoma in situ) refractory to Bacillus Calmette-Guerin 
(BCG) therapy with primary endpoints: Disease Free Survival (DFS) and pCRR. Furthermore, 
another phase II trial is currently exploring the role of Atezolizumab in patients with high-grade 
urothelial bladder cancer refractory to BCG (NCT02844816). 
Pembrolizumab and Avelumab are being tested as maintenance therapy after platinum-containing 
first line therapy. The phase III trial JAVELIN Bladder 100 study (NCT02603432) is currently 
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ongoing to compare maintenance treatment with Avelumab plus best supportive care (BSC) versus 
BSC alone in metastatic UC patients who have not progressed during or following First-line 
systemic therapy. Primary endpoint is OS and approximately 668 patients are planned to be 
enrolled. This study will be completed in July 2019. The phase II trial (NCT02500121) is currently 
testing Pembrolizumab as maintenance therapy after standard First line chemotherapy in patients 
with locally advanced or metastatic UC. This study has 6-months PFS as primary endpoint and 
planned an enrolment of 200 patients with stable disease (SD), complete response (CR) or partial 
response (PR) after platinum-based first-line that will be randomized to receive Pembrolizumab or 
placebo. 
Regarding adjuvant setting a large randomized phase III trial is testing Nivolumab as postoperative 
treatment in patients with high-risk invasive urothelial carcinoma (NCT02632409). The planned 
enrolment of this placebo controlled is 640 patients with primary endpoint DFS. The study started 
in February 2016 with estimated primary completion date in October 2020. The phase III 
(NCT02450331) is evaluating the different DFS in 700 patients with histologically confirmed 
muscle invasive urothelial carcinoma of the bladder or upper urinary tract. In this study patients will 
be randomized to receive Atezolizumab (1200 mg Q3W for 16 cycles) or observation. The planned 
completion date is estimated in April 2022. 
Regarding first-line therapy Atezolizumab and Pembrolizumab are being tested in phase II clinical 
trials in patients unfit or refuising platinum based therapy (NCT02451423, Keynote 052). Of note 
preliminar results of Keynote 052 study seams to show an interesting ORR on the analysis of the 
first 100 patients enrolled (ORR: 24%) [15].  
An ongoing phase III trial (NCT02516241; DANUBE) of Durvalumab as a monotherapy or 
combined with Tremelimumab (CTLA4 inhibitor) versus standard-of-care chemotherapy 
(gemcitabine plus cisplatin or gemcitabine plus carboplatin) is currently recruiting patients with 
metastatic or unresectable UC. This 3-arm trial is expected to be completed in 2019 and OS is the 
primary endpoint. 
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3. EHNANCING IMMUNOTHERAPIES THROUGH COMBINATION STRATEGIES 
As already discussed, not all subjects respond to immune-checkpoint inhibitors and so the 
development of new strategies aimed to increase the number of patients who can benefit from these 
treatments it’s strictly required. 
There are several evidences showing that previously inflamed tumour could more benefit from 
immune-checkpoints inhibitors while “no-T cell inflamed tumours” not [24-26]. Tumours adopt 
several mechanisms through which became ‘invisible’ to immune cells. The absence of priming 
signals, the activation of tolerance signals by suppressive cytokines or recruitment of regulatory T 
cells, the absence of antigens or the absence of antigen presenting cells and the stromal interactions 
are possible strategies adopted by cancer cells to escape from immune-pressure. 
The combination between immune-checkpoint inhibitors and other drugs could be a key option able 
to overcome the tumour immune escape. To date, several trials are testing different combination 
strategies with immune-checkpoint inhibitors and target agents, chemotherapy, radiotherapy, other 
immune agents and other immune-checkpoint inhibitors (Figure 1) to overcome the immune tumour 
resistance and improve clinical outcome in patients with urothelial carcinoma. 
 
 
3.1 PD-1/PD-L1 and CTLA-4 inhibitors combination 
 
As already descripted, PD-L1/PD-1 and CTLA-4 inhibitors adopt a different mechanism to enhance 
immune response against tumours. Indeed, inhibition of PD-L1/PD-1 pathway lead to a restored 
activity of pre-activated exhausted T cells while inhibition of CTLA-4 receptors resulting in an 
effector T Cell amplification in early stages of antigen presentation. As these are different pathway 
of a common cascade resulting in T Cell activation, a dual immune-checkpoint blockade could be a 
key option that would allow reaching better clinical outcome than PD-L1/PD-1 or CTLA-4 
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monotherapy. This combination strategy has been already tested in melanoma with significant 
improvement of long-term responses compared to single agent monotherapy [27,28]. The 
Nivolumab and Ipilimumab combination is currently being tested in a large randomized clinical 
trial where patients with untreated metastatic or unresectable UC will be randomized to receive the 
immune checkpoints combination or platinum based chemotherapy (NCT03036098; CheckMate 
901). The estimated enrolment of this trial is 690 patients with PFS and OS as primary endpoint. 
Another large phase II clinical trial (NCT01928394) is currently comparing the Nivolumab and 
ipilimumab association to Nivolumab monotherapy in patients with advanced triple-negative breast 
cancer, gastric cancer, pancreatic adenocarcinoma, small cell lung cancer, bladder cancer, and 
ovarian cancer.  
Another phase III clinical trial (NCT03084471; STRONG) is currently comparing the combination 
Durvalumab-Tremelimumab to Durvalumab monotherapy in advanced solid malignancies with an 
estimated enrolment of 1200 patients. The aim of this study is to evaluate the safety profile of the 
combination immunotherapy with an estimated completion data in April 2022. Of note, the 
combination of Durvalumab with Tremelimumab is under investigation also in patients with 
muscle-invasive, high-risk UC who are ineligible for cisplatin-based neoadjuvant chemotherapy 
(NCT02812420). 
 
3.2 Immune-checkpoint inhibitors and other immune agents 
 
Another interesting strategy aimed to enhance the therapeutic potential of immune-checkpoint 
inhibitors consists of a combination between these agents and other able to increase the tumour 
associated immune-stroma. BCG instillation is able to induce an immune response against tumour 
cells and it’s currently approved in early stage of urothelial bladder cancer with high risk of 
recurrence after local resection [29]. The association between BCG acting as an immune cells 
recruiter and the PD-1 inhibitor Pembrolizumab and PD-L1 inhibitor Atezolizumab is currently 
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being explored in early stage of high risk UC (NCT02324582, NCT02808143 with Pembrolizumab 
and NCT02792192 with Atezolizumab).  
Since activated-T Cells are the target of PD-1/PD-L1 inhibitors another approach is to increase the 
number of these cells. Indeed, tumours with low mutational load are associated with lower 
expression of cancer associated antigen/neo-antigen leading to small or absent tumour associated 
immune-infiltrate and lower activated T-Cells and Memory T-Cells resulting in a PD-1/PD-L1 and 
CTLA-4 inhibition escape [30-36]. The combination therapy with immune-checkpoint inhibitors 
and vaccines or tumour associated lymphocytes could help the recruitment of activated T-Cells and 
Memory T-Cells and it is currently being tested in phase I and phase II clinical trials in patients 
with advanced or recurrent malignancies including also UC (NCT02432963, NCT01174121) and as 
adjuvant treatment in patients with melanoma, lung or bladder cancer (NCT02897765).  
Another strategy working in this way consists of the association between immune checkpoint 
inhibitors with cytokines able to enhance T-Cell activity. Interferon  increases dendritic cells 
functions and promotes T Cell activation showing a promising activity when associated to the 
CTLA-4 inhibitor Tremelimumab in patients with stage IV melanoma [37]. The association of 
Nivolumab and interferon  is currently being tested in patients with advanced solid tumours 
including also patients with UC (NCT02614456). The fusion protein NHS-IL 12 is composed of 
two molecules of IL-12 fused to a tumour necrosis-targeting IgG1 (NHS76). It has shown 
promising anti-tumour activity in murine tumour models [38]. The safety of the combination 
between the anti-PD L1 Avelumab and NHS-IL 12 is under investigation in a phase I clinical study 
(NCT02994953). The combination therapy between Durvalumab and Tremelimumab in association 
with polyICLC, a ligand of toll like receptor-3, is under investigation in patients with biopsy 
accessible solid tumours (NCT02118337).  
The association between PD-L1 and PD-1 inhibitors is another option under investigation. Indeed, 
an ongoing phase 1 open-label (NCT02118436), dose-escalation and expansion study is recruiting 
patients with relapsed/refractory advanced solid malignancies to receive Durvalumab in 
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combination to MEDI0680, a humanized IgG4κ monoclonal antibody specific for human PD-1 that 
blocks interaction with PD-L1 and programmed cell death ligand-2 (PD-L2). Of note, preliminary 
results showed a 15% ORR and a 35% DCR. The most common drug-related adverse events were 
pruritus (17%), fatigue (13%), diarrhoea (13%), flushing (10%), peripheral edema (10%) and 
pyrexia (10%) [39]. 
 
3.3 Immune-checkpoint inhibitors and oncolytic viruses 
 
Oncolytic viruses are novel promising agents against cancer. These modified viruses could be 
directed against specific targets, perform a lytic effect on tumour cells and act as immune 
stimulators [40,41]. Thanks to these proprieties, oncolytic viruses are currently testing in several 
clinical trials. Regarding UC, CA21 and enadenotucirev are currently under evaluation. The 
oncloytic coxsackievirus CA 21 target the Intercellular Adhesion Molecule I (ICAM-1) on tumour 
cells surface. It has already showed promising activity in melanoma as well as in non muscular 
invasive bladder cancer [42,43]. To date the safety of combination between pembrolizumab and 
CA21 in advanced or recurrent tumours is being evaluated in phase I clinical trial (NCT02043665). 
Enadenotucirev is an oncolytic group B adenovirus able to replicate in cancer cells leading to their 
lysis. It showed a safety profile in patients with metastatic epithelial cancer [44] and is currently 
tested with Pembrolizumab in metastatic solid tumours (NCT02636036). 
 
3.4 Immune-checkpoint inhibitors combination and chemo/radio therapy 
 
Radiotherapy and chemotherapy could play a key role as agents able to overcome immune-tumour 
escape. Indeed, tumour irradiation stimulates an intensive inflammation in the site of application, 
promotes the production of adhesion molecules and MHC I and activates an intensive flux of CD8+ 
lymphocytes. Through these mechanisms irradiation drives an immune response that leads also to 
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the regression of distant and un-irradiated tumour lesions (Abscopal effect) [45,46]. Not surprising, 
immune-checkpoint therapy combination with tumours irradiation represents an emerging strategy 
with a strong biological rational [46,47]. Several phase I/II clinical trials are exploring the 
association between Pembrolizumab and radiation therapy with (NCT02662062, NCT02621151) or 
without (NCT02560636) chemotherapy in different stage of the disease. Among them, a phase I-II 
study led by Sundahl et al. is exploring the efficacy and safety of fixed-dose stereotactic body 
radiotherapy with sequential or concurrent Pembrolizumab in patients with metastatic UC [48]. On 
the other hand, the association between Durvalumab and radiation therapy is under investigation as 
adjuvant treatment in a phase I/II trial (NCT02643303). 
Chemotherapy has represented the standard therapy for metastatic or locally advanced unresectable 
UC and it’s likely that it will play an important role also in association with immune-checkpoints 
inhibitors. There are several proposed mechanisms through which chemotherapy could overcome 
immune-tumour escape. First the lytic effect done by antiblastic agents could lead to the 
presentation of antigen and neo-antigen resulting in T-Cell activation. Second, through the 
elimination of immunosuppressive cells could restore immune activity against tumours. Third, it 
could drive a better penetration of immune cells in tumour stroma. Furthermore, there are evidences 
that patients who received chemotherapy after immune treatment could have a better response to 
antiblastic agents suggesting a synergic effect between chemotherapy and immune-therapy [49,50]. 
This approach is currently investigated by several clinical trials in UC. Of note, two phase III 
clinical trials are exploring the association between Pembrolizumab or Atezolizumab and 
chemotherapy. The KEYNOTE 361 (NCT02853305) is a phase III randomized clinical trial with an 
estimated enrolment of 990 patients with metastatic or locally advanced UC who will be 
randomized to receive Pembrolizumab (200 mg every 3 weeks) with or without platinum based 
chemotherapy or chemotherapy alone. PFS and OS are primary endpoints with estimated primary 
completion data expected in March 2019 and study completion data in April 2020. 
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The IMvigor130 (NCT02807636) is a randomized placebo-controlled phase 3 clinical trial where 
1200 patients with metastatic or locally advanced unresectable urothelial cancer will be randomized 
to receive Atezolizumab (1200 mg every 3 weeks) alone or in combination with platinum based 
chemotherapy. Patients enrolled in comparator arm will receive standard platinum based 
chemotherapy with placebo. This study will test safety and the clinical efficacy of Atezolizumab 
monotherapy or combination with primary endpoints PFS, OS and adverse events rate. The 
estimated primary completion data is expected in December 2018 while the completion of study in 
July 2020. 
 
3.5 Immune checkpoint inhibitors combination with target therapy 
 
No targeted therapy as well as no anti-angiogenic agents have shown significant clinical results in 
patients with UC. Nonetheless, the combination between immune-checkpoints inhibitors and target 
agents is under investigation in several phase I/II clinical trials. The rational of this association 
resides in the hypothesis that inhibition of specific and altered pathway leads to a better response to 
immunotherapy. Indeed, the inhibition of key signalling such as VEGF (Vascular Endothelial 
Growth Factor), FGF (Fibroblastic Growth Factor), MET (Mesenchimal-Epithelial Transition) 
could led to the direct exposure of tumour cells to immune cells, to a reduction of regulatory 
immune cells and finally to tumour cell lysis with expression of antigen and neoatingen [51,52].  
Regarding angiogenesis inhibitors, the VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2) 
inhibitor Ramucirumab and the anti-VEGF Bevacizumab are currently being tested in combination 
with Pembrolizumab (NCT02443324) and Atezolizumab (NCT01633970) in patients with 
advanced solid tumours including also patients with advanced UC. Levatinib is a VEGFR1, 
VEGFR2 and VEGFR3 kinase inhibitor that is under investigation in combination with 
Pembrolizumab in a phase I (NCT03006887) and a phase I/II clinical trials (NCT02501096). 
EphB4-HAS is a recombinant fusion protein composed of the extracellular domain of the human 
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receptor tyrosine kinase ephrin type-B receptor 4 (sEphB4) and human serum albumin (HSA). This 
protein acts interfering the binding of Ephirin b2 (Efnb2) to the Ephrin B4 and A3 receptors 
(EphB4 and EphA3), resulting in angiogenesis inhibition in tumour cells overexpressing Efnb2 and 
EphB4. The combination between Pembrolizumab and EphB4-HAS protein is currently being 
tested in a phase II trial evaluating the clinical activity of this association in previously treated 
patients with locally advanced or metastatic UC (NCT02717156). 
About drugs targeting specific target of the tumour related stroma, the VEGFR 1-3, FGFR 1-3 
(Fibroblastic Growth Factor Receptor 1-3), PDGFR- (Platelet-Derived Growth Factor Receptor ) 
inhibitor Nintedanib and the FGFR-3 inhibitor B-701 are currently under investigation in 
combination with Pembrolizumab in two phase I studies (NCT02856425, NCT02925533). 
INCB054828 is an orally bioavailable inhibitor of FGFR 1-3. A phase I/II trial (NCT02393248) 
enrolling patients with advanced solid tumour is comparing the activity of INCB054828 in 
association with Pembrolizumab or with chemotherapy (Gemcitabine + cisplatin or docetaxel). 
Pexidartinib (PLX3397) is an interesting tyrosine-kinase inhibitor of the stem cell factor receptor 
(KIT), colony-stimulating factor-1 receptor (CSF1R) and FMS-like tyrosine kinase 3 (FLT3). These 
pathways play a key role in tumour proliferation and macrophages, osteoclasts and mast cells down-
modulation resulting in stimulation of osteolytic metastatic process. The Pembrolizumab and 
PLX3397 combination is under evaluation in a phase I/II clinical trials enrolling patients with 
advanced solid tumours (NCT02452424). 
The safety profile of the combination between Nivolumab and the MET and VEGFR2 kinases 
inhibitor cabozantinib is under investingation in a phase I study (NCT02496208) in 113 patients 
with locally advanced or metastatic genitourinary tumours. 
The phase Ib NCT02546661 is a randomised multi-drug trial testing the PD-L1 inhibitor 
Durvalumab, the nuclear enzyme poly (ADP-ribose) polymerase (PARP) Olaparib, the mammalian 
target of rapamycin (mTOR) inhibitor Vistusertib, the FGFR inhibitor AZD4547 and the WEE1 
tyrosine kinase inhibitor AZD1175.  
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This study is evaluating the safety profile of these association and has an estimated enrollment of 
110 patients with muscle invasive bladder cancer progressed on prior treatment who will be 
randomized to receive: AZD4547, Durvalumab with AZD4547, Durvalumab with Olaparib, 
Durvalumab with AZD1775, Durvalumab with Vistusertinib or Durvalumab monotherapy.  
Another interesting agent under inverstigation is Vorinostat that is a compound able to bind the 
catalytic domain of the histone deacetylases resulting in accumulation of hyperacetylated histones 
and trascription factors [53]. Hyperacetylation of hystone results in upregulation of cyclin-
dependant kinase p21 and in a G1 arrest of the cell cycle. Furthermore, hyperacetylation of non-
histone proteins such as p53, alpha tubulin and heat-shock protein 90 leads to an additional anti-
proliferative effect. A phase I/II study is evaluating the safety profile and the clinical activity of the 
association between Pembrolizumab and Vorinostat in previously treated patients with advanced or 
metastatic renal cell carcinoma and UC (NCT02619253). 
 
4. OTHER IMMUNOLOGICAL APPROACH 
Interleukin-15 is a cytokine who plays a key role in activation, development and proliferation of 
CD8+ Memory T cells and natural killer cells. ALT-803 is a IL-15 mutant able to enhance IL-15 
activity that has demonstrated safety and promising anti-tumour activity in solid and haematological 
tumour models [54,55]. Several trials are currently testing this agent in combination with BCG in 
high risk not muscle invasive bladder cancer (NCT03022825, NCT02138734). 
ALT-801 is a novel immunotherapeutic fusion protein composed of interleukin-2 linked to a single 
chain T cell receptor domain who has already shown to be a safety and active treatment against 
solid and haematological malignancies [56,57]. Furthermore, ALT-801 has been tested with 
platinum based chemotherapy in patients with advanced or metastatic UC showing an interesting 
ORR (35%) burdened by a significant toxicity (50% of patients with Grade 3-4 adverse related 
events) [58].  Future trials will explore the role of this agent in UC (NCT01625260, 
NCT01326871).  
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CD137 is a costimulatory member of the TNF (Tumour Necrosis Factor) receptor superfamily that 
is expressed on T Cells, dendidritc cells and natural killer cells after antigen mediated activation. 
CD137 activation results in cytokine induction and stimulated activity of T-Cells leading to an 
enhanced immune-response against tumour cells [59,60]. Urelumab (BMS-663513) is a fully 
human IG4 antibody able to blind and agonist CD137 receptor has already been tested in small 
phase I clinical studies showing a safety profile [61]. A phase II clinical trial (NCT02845323) will 
compare this combination treatment to Nivolumab monotherapy as neo-adjuvant treatment in 
patients unfit to Cisplatin standard therapy. 
CD27 is another costimulatory receptor member of the TNF receptor superfamily. CD27, which 
through the interaction with its ligand (CD70), plays an important role in generation and 
maintenance of immune response especially through B-Cell activation and immunoglobulin 
synthesis [62]. Varlilumab is a human monoclonal antibody with agonistic activity to CD27 
receptor that is currently testing with Atezolizumab in a phase I clinical trial exploring the safety 
profile and the clinical activity of this combination (NCT02543645) [63] .  
B7-H3 belongs to B7 superfamily and acts a costimulatory molecule who leads after itself 
stimulation to a down-modulation of T-Cell activation [64] This molecule has been recently 
associated with specific immune-pathways and poor clinical outcome in prostate cancer [65]. 
Enoblituzumab (MGA 271) is a humanized monoclonal antibody targeting B7-H3. Association 
between Enoblituzumab and Pembrolizumab (NCT02475213) or Ipilimumab (NCT02381314) is 
currently exploring the safety of these agents in advanced or metastatic malignancies including UC. 
MGD009 is a protein targeting B7-H3 and CD3 who redirects CD3 expressing T Cell to kill B7-H3 
expressing cells. Currently, MGD009 safety profile is under investigation in a phase I clinical trial 
in patients with advanced solid tumours, including also patients with bladder cancer 
(NCT02628535).  
Acalabrutinib is an orally available inhibitor of Bruton’s tyrosine kinase (BTK). BTK plays a key 
role in lymphocites B activation and proliferation and is generally overexpressed in B-cell 
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malignancies. The clinical activity of the association between Acalabrutinib (ACP-196) and 
Pembrolizumab compared to Pembrolizumab monotherapy is currently under investigation in a 
phase II clinical trial (NCT02351739). 
CM-24 is a humanized monoclonal immunoglobulin targeting the anti-carcinoembyonic antigen 
(CEA)-related cell adhesion molecule 1 (CEACAM 1). This adhesion molecule is expressed on the 
surface of tumour cells as well as on the surface of several immune cells and its inhibition leads to 
an enhances activation of cytotoxic T-Lymphocytes and natural killer cells [66]. A phase I trial is 
evaluating the safety profile of the association between Pembrolizumab and CM-24 in patients with 
advanced solid tumours (NCT02346955). 
The IDO (indoleamine 2,3-dioxygenase) catalyzes the cleavage of L-Tryptophan resulting in the 
production of kynurenine. The accumulation of kynurenine as well as the depletion of tryptophan 
resulting in an increased numbers of T regs lymphocyte leading to a reduction of active and effector 
T cells [67]. Epacadostat is an IDO inhibitor which is currently testing in several solid tumours in 
combination with CTLA-4 and PD-1 inhibitors. Phase I and II clinical trials are currently exploring 
the safety profile of the combination therapy between Durvalumab and Epacadostat  
(NCT02318277) as well as Atezolizumab and Epacadostat (NCT022981539). 
There are further evidences that the depletion of arginine in arginase-expressing myeloid cells leads 
to an inhibition of proliferation and activity of lymphocytes resulting in an immune-response 
inhibition [68]. To overcome the immunosuppressive effect caused by arginine depletion a human 
arginases inhibitor has been developed. A phase I trial (NCT02903914) is currently testing the 
safety profile of the arginases inhibitor CB-1158 alone or in combination with Nivolumab in 236 
patients with advanced solid malignancies including UC.  
The adenosine A2A receptor also known as ADORA2A is an adenosine receptor expressed basal 
ganglia, vasculature, and platelets.  Several immune cells like macrophages, dendritic cells, natural 
killer cells and T-lymphocites expressed this receptor whose activation leads to an inhibition of the 
immune response [69]. CPI-444 is a small molecule that acts as an antagonist of Adenosine A2A 
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receptor. It’s safety profile in combination with Atezolizumab is currently under investigation in 
patients with advanced solid tumours including also patients with UC (NCT02655822). 
 
5. FUTURE PERSPECTIVES 
Chemotherapy has represented the standard treatment for locally advanced and metastatic UC but 
this scenario is about to change. The important results achieved suggesting that immunotherapy will 
probably be the future treatment paradigm of the disease. Immune-checkpoint inhibitors represent a 
realistic hope for patients with UC. Indeed, they appear to significantly improve the overall survival 
of these patients and thanks to a better safety profile compared to chemotherapy they could be 
proposed also in patients with poor clinical features. 
Future trial will explore the role of immune-checkpoint inhibitor in other setting of the disease 
including: early stages, pre-operative and adjuvant setting and their efficacy as First line treatment. 
Furthermore, another issue to be explored is whether combination between immune-checkpoint 
inhibitors and other agents including other immune-agents, target drugs, oncolytic viruses, 
chemotherapy and radiotherapy leads to a high percentage of patients who can benefit from 
immunotherapy. The possibility that several patients could obtain stable and durable response have 
lead to the development of several clinical trials exploring different kind of combination between 
these agents boosting a revolution that has just begun. 
 
CONCLUSION 
Chemotherapy has represented the standard treatment for locally advanced and metastatic urothelial 
carcinoma but this scenario is about to change. The important results achieved suggesting that 
immunotherapy will probably be the future treatment paradigm of the disease. Immune-checkpoint 
inhibitors represent a realistic hope for patients with UC. Indeed, they appear to significantly 
improve the overall survival of these patients and thanks to a better safety profile compared to 
chemotherapy they could be proposed also in patients with poor clinical features. 
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Future trial will explore the role of immune-checkpoint inhibitor in other setting of the disease 
including: early stages, pre-operative and adjuvant setting and their efficacy as First line treatment. 
Furthermore, another issue to be explored is whether combination between immune-checkpoint 
inhibitors and other agents including other immune-agents, target drugs, oncolytic viruses, 
chemotherapy and radiotherapy leads to a high percentage of patients who can benefit from 
immunotherapy. The possibility that several patients could obtain stable and durable response have 
lead to the development of several clinical trials exploring different kind of combination between 
these agents boosting a revolution that has just begun. 
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Table Legend 
 
Table 1. Ongoing phase III clinical trials with an immunotherapy agent in urothelial cancer. 
Table 2. Ongoing phase II/III,II, I/II and I studies with immune-checkpoints inhibitors, CTLA-4 
Inhibitors and other immuno agents.  
OS: Overall Survival, PFS: Progression Free survival, CRR: Complite response rate, DFS: Disease 
Free Survival. 
 
 
Figure Legend 
Figure 1. Immunotherapeutic approaches in bladder cancer. 
 
 
 
 
  
 
TRIAL NAME 
 
IMMUNOTHERAPIC 
AGENTS 
 
 
TREATMENT ARMS 
 
POPULATION 
 
PLANNED 
PATIENTS 
(N) 
 
PRIMARY 
ENDPOINT 
 
DATE 
STARTED 
PLANNED 
COMPLATATION 
DATE 
NCT02853305 
Keynote-361 
Pembrolizumab 
A) Pembrolizumab 200 mg 
IV on Day 1 of each 3-week 
cycle for a maximum of 35 
doses 
B) Pembrolizumab + 
Chemotherapy 
(Cisplatin/Gemcitabine, or 
Carboplatin/Gemcitabine) 
C) Chemotherapy 
(Cisplatin/Gemcitabine, or 
Carboplatin/Gemcitabine) 
First line therapy 
Patients with previously untreated 
unresectable or metastatic urothelial 
cancer 
 
990 
PFS 
OS 
September 
2016 
March 
2020 
NCT03036098 
Nivolumab 
Ipilimumab 
A) Nivolumab + Ipilimumab 
combination 
B) Standard of care 
Chemotherapy 
(Cisplatin/Gemcitabine, or 
Carboplatin/Gemcitabine) 
First line therapy 
Patients with previously untreated 
unresectable or metastatic urothelial 
cancer 
 
690 
PFS 
OS 
March  
2017 
December 
2022 
NCT02450331 Atezolizumab 
A) Atezolizumab IV infusion 
1200 mg q3w for 16 cycles 
(up to 1 year) 
B) Observation 
Adjuvant therapy 
Patients with PD-L1 positive, high 
risk muscle-invasive bladder cancer 
after cystectomy 
700 
 
DFS 
 
 
June 2017 
April 2022 
NCT02807636 
IMvigor130 
 
Atezolizumab 
A) Atezolizumab IV infusion 
1200 mg q3w and 
carboplatin AUC 4,5 mg/mL 
min and gemcitabine IV 
infusion 1000 mg/mq on 
day 1 and 8 of each 21 day 
cycle 
B) placebo IV infusion q3w 
with carboplatin and 
gemcitabine 
First line therapy 
Pz with loaclly advanced or 
metastatic UCB who are ineligible to 
receive cisplatin-based therapy/ 
 
1200 
PFS 
OS 
AEs 
June 2016 
July 2020 
 
NCT02603432 
JAVELIN 
Bladder 100 
Avelumab 
A) Avelumab q2w in 4 week 
cycles plus BSC 
B) BSC 
Maintaince treatment after first-line 
chemotherapy 
668 OS April 2016 July 2020 
  
NCT03084471 
Durvalumab  
Tremelimumab 
Durvalumab monotherapy 
or Durvalumab + 
Tremelimumab combination 
Metastatic or locally advanced 
urothelial carcinoma progressed to 
First line therapy/Advanced 
maligancies 
1200 
Safety: 
number and 
percentage 
of 
participants 
with AESI 
April 2017 April 2022 
NCT02516241 
DANUBE 
Durvalumab 
tremelimumab 
A) Durvalumab + 
tremelimumab 
B) Durvalumab 
C) Standard of care 
(Chemotherapy 
Cisplatin, Carboplatin and 
Gemcitabine) 
Metastatic or locally advanced 
urothelial carcinoma 
1005 
PFS 
OS 
November 2015 July 2019 
 
Table 1. Ongoing phase III clinical trials with an immunotherapy agent in urothelial cancer.  
IV: intravenous; q3w: every 3 weeks; q2w: every 2 weeks; BSC: Best Supportive Care; DFS: Disease-Free Survival; PFS: Progression Free Survival; OS: 
Overall Survival; AEs: Percentage of Participants with Adverse Events; AESI: adverse events of special interest. 
 
  
Study  Drug N Setting Comparator arm Phase Primary 
outcome 
PD-1 inhibitors 
NCT02500121 Pembrolizumab 200 maitenance after I line 
 
Placebo II 6 months - 
PFS 
 
NCT02736266 Pembrolizumab 90 Neoadjuvant 
 
NO II CRR 
 
NCT02625961 Pembrolizumab 260 BCG failure, pT1-Ta, CIS NO II DFS/CRR 
 
NCT02662062 
 
Pembrolizumab + Cisplatin 
and RT 
30 T2-T4a, Nx or N0 
urothelial carcinoma 
 
NO II Safety 
NCT02621151 
 
Pembrolizumab 
+Gemcitabine /RT 
54 T2-T4a, N0, M0 
 
NO II 2year DFS 
NCT01174121 
 
Pembrolizumab + TIL 290 Advanced malignancies NO II ORR 
NCT02690558 
 
Pembrolizumab + Cisplatin - 
Gemcitabine 
39 Neoadjuvant 
 
NO II ORR 
NCT02581982 
 
Pembrolizumab 
+ Paclitaxel 
27 previously treated 
patients with 
metastatic or locally 
advanced UC 
 
NO II ORR 
NCT02351739 
 
Pembrolizumab + 
ACP-196 
75 previously treated 
patients with 
metastatic or locally 
advanced UC 
Pembrolizumab II ORR 
 
NCT02717156 
 
Pembrolizumab + 
EphB4-HSA fusion protein 
60 previously treated 
patients with 
metastatic or locally 
advanced UC 
NO II Safety 
NCT02845323 
 
Nivolumab + Urelumab  
44 
Neoadjuvant unfit to 
cisplatin 
Nivolumab II ORR 
NCT01928394 
 
Nivolumab + ipilimumab 1150 Advanced malignancies Nivolumab/Nivolumab 
+ ipilimumab/ 
II ORR 
NCT02365766 
 
Pembrolizumab + 
Gemcitabine 
81 Neoadjuvant unfit to 
cisplatin 
NO I/II Safety/ORR 
NCT02437370 
 
Pembrolizumab + 
Gemcitabine/docetaxel 
38 previously treated 
patients with 
metastatic or locally 
advanced UC 
NO I/II Safety 
NCT02619253 
 
Pembrolizumab + Vorinostat 42 previously treated 
patients with 
metastatic or locally 
advanced UC 
NO I/II Safety 
NCT02501096 
 
Pembrolizumab + Levatinib 250 Advanced malignancies NO I/II Safety 
NCT02393248 
 
Pembrolizumab + 
INCB054828 
 
150 Advanced malignancies CT + INCB054828 
 
I/II Safety 
 
  
NCT02925533 
 
Pembrolizumab + B 701 
 
12 previously treated 
patients with 
metastatic or locally 
advanced UC 
 
 
NO I Safety 
 
NCT02443324 
 
Pembrolizumab + 
Ramucirumab 
 
155 Advanced malignancies NO I  
Safety 
 
 
NCT03006887 
 
Pembrolizumab + Levatinib 
 
10 Advanced malignancies NO I Safety 
 
 
NCT02856425 
 
Pembrolizumab + 
Nintendanib 
 
18 Advanced malignancies NO I Safety 
 
NCT02043665 
 
Pembrolizumab + CVA21 
 
90 Advanced malignancies NO I ORR 
 
NCT02346955 
 
Pembrolizumab + CM-24 
(MK-6018) 
 
27 Advanced malignancies NO I Safety 
 
 
NCT02324582 
 
Pembrolizumab + BCG 
 
15 high risk superficial 
bladder cancer 
 
 
NO 
I Safety 
 
NCT02808143 
 
Pembrolizumab + BCG 
 
27 high risk superficial 
bladder cancer 
refractory to BCG 
 
NO I Safety 
 
NCT02432963 
 
 
 
Pembrolizumab + Vaccine 
therapy 
19 Advanced malignancies NO I Safety 
 
NCT02475213 
 
 
Pembrolizumab + 
enoblituzumab 
 
75 
Advanced malignancies NO I Safety 
 
 
NCT02560636 
 
Pembrolizumab + 
Radiotherapy 
 
34 Metastatic or locally 
advanced UC 
NO I Safety 
NCT02826564 
 
Pembrolizumab + 
Stereotactic Body 
Radiotherapy 
 
20 previously treated 
patients with 
metastatic or locally 
advanced UC 
 
NO I Safety 
NCT02614456 
 
Nivolumab + interferon 
gamma 
 
15 Advanced malignancies NO I Safety 
NCT02897765 
 
Nivolumab + NEO-PV-01 
 
 
90 Advanced malignancies NO I Safety 
 
NCT02496208 
 
Nivolumab + Cabozantinib 
 
113 previously treated 
patients with 
metastatic or locally 
advanced UC 
 
Nivolumab + cabozantinib + 
Ipilimumab 
 
I Safety 
NCT02903914 
 
Nivolumab + CB-1158 
 
236 Advanced malignancies Nivolumab / CB 1158 
 
I Safety 
NCT02636036 
 
Nivolumab + Enadenotucirev 
 
30 Advanced malignancies NO I Safety 
  
PD-L1 Inhibitors       
NCT02662309 
 
Atezolizumab 
 
 
85 neoadjuvant therapy 
for cT2-4A Urothelial 
Bladder Cancer 
 
NO II CRR 
NCT02451423 
 
Atezolizumab 
 
42 patients refuising or 
inelegible for 
neoadjuvant 
chemotherapy 
 
Atezolizumab 1200mg for 
1,2 or 3 cycles 
II change in 
CD3+/t0 rate 
NCT02844816 
 
Atezolizumab 
 
148 High grade non muscle 
invasive bladder cancer 
refractory to BCG 
 
NO II CRR 
NCT02901548 
 
Durvalumab 
 
34 High grade non muscle 
invasive bladder cancer 
refractory to BCG 
 
NO II CRR 
NCT02527434 
 
Durvalumab +/-
temelimumab 
 
89 Advanced  
malignancies 
 
Durvalumab +/-
temelimumab to disease 
progression to 
tremelimumab 
 
II ORR 
NCT02792192 
 
Atezolizumab + BCG 
 
 
70 High grade non muscle 
invasive bladder cancer 
BCG naive or refractory 
to BCG 
 
Atezolizumab 
 
I/II safety CRR 
 
NCT02543645 
 
Atezolizumab + Varlilumab 
 
55 Advanced  
malignancies 
 
NO I/II safety CRR 
 
NCT01693562 
 
 
Durvalumab 
 
1173 Advanced  
malignancies 
 
NO I/II Safety 
 
NCT02318277 
 
Durvalumab + Epacadostat 
 
185 Advanced  
malignancies 
 
NO I/II Safety 
NCT02891161 
 
Durvalumab + RT 
 
42 Urothelial carcinoma (T 
2-4 N 0-2 M0) 
 
NO I/II Safety,DCF, 
PFS 
NCT02643303 
 
Durvalumab + 
tremelimumab + PolyICLC 
 
102 subjects with 
advanced, measurable, 
biopsy-accessible 
cancers. 
 
Durvalumab + 
tremelimumab 
 
I/II Safety/ORR 
NCT02118337 
 
Durvalumab + AMP 514 
 
97 Advanced  
malignancies 
 
AMP-514 monotherapy I/II Safety 
NCT01633970 
 
Atezolizumab + bevacizumab 
 
240 Advanced  
malignancies 
 
Atezolizumab + 
bevacizumab and/or CT 
 
I Safety 
NCT02298153 
 
Atezolizumab + Ecadostat 
 
118 Advanced  
malignancies 
 
NO I Safety 
  
 
NCT02655822 
 
Atezolizumab + CPI-444 
 
534 Advanced  
malignancies 
 
NO I Safety 
NCT01772004 
 
Avelumab 
 
1706 Advanced  
malignancies 
 
NO I Safety 
NCT01943461 Avelumab 
 
57 Advanced  
malignancies 
 
NO I Safety 
NCT02994953 Avelumab + NSH-IL12 
 
30 Advanced  
malignancies 
 
NO I Safety 
NCT02546661 
 
Durvalumab + 
olaparib/AZD4547/Vistuserti
nib 
 
110 Muscle invasive 
bladder cancer 
progressed on prior 
treatment 
 
Durvalumab/olaparib/AZD4
547/vistusertinib 
monotherapy 
 
I Safety 
NCT02812420 
 
Durvalumab + 
tremelimumab 
 
15 muscle invasive bladder 
cancer inelegible for 
cisplatin based 
neoadjuvant therapy 
 
NO I Safety 
CTLA-4 
Inhibitors and 
other immuno 
agents 
      
NCT03022825 
 
 
ALT-803 + BCG 
 
80 High grade non muscle 
invasive bladder cancer 
refractory to BCG 
 
 
BCG II/III CRR 
 
NCT01524991 
 
Ipilimumab + platinum based 
chemotherapy 
 
36 Patients with untreated 
metastatic or locally 
advanced UC 
NO II  
one year OS 
 
NCT02138734 
 
ALT-804 + BCG 
 
81  
non muscle invasive 
bladder cancer 
 
 
BCG 
I/II Safety 
NCT01625260 
 
ALT-801 + Gemcitabine 
 
52 High grade non muscle 
invasive bladder cancer 
refractory to BCG 
 
NO I/II Safety 
NCT01326871 
 
ALT-801 + Cisplatin and 
Gemcitabine 
 
90 Metastatic or muscle 
invasive bladder cancer 
 
ALT-801 - Gemcitabine I/II Safety 
NCT02381314 
 
Ipilimumab + Enoblituzumab 
 
84 Advanced Malignancies 
 
NO I Safety 
NCT02628535 
 
MGD-009 114 Advanced Malignancies 
 
NO I Safety 
 
 
Table 2. 
Ongoing phase II/III,II, I/II and I studies with immune-checkpoints inhibitors, CTLA-4 Inhibitors and 
other immuno agents.  
OS: Overall Survival, PFS: Progression Free survival, CRR: Complite response rate, DFS: Disease 
Free Survival 
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Highlights 
 
1. Atezolizumab and Pembrolizumab showed in phase II (Atezolizumab and Pembrolizumab) 
and phase III (Pembrolizumab) trials to improve clinical outcome of patients progressed to 
platinum based therapy. 
 
2. Atezolizumab failed to show OS benefit over chemotherapy in a phase III trial for patients 
progressed to platinum based therapy. 
 
3. Immunotherapy improve clinical outcome of patients unfit to standard first line platinum 
therapy 
 
4. We describe the active or ongoing clinical trials involving Programmed Death Ligand 1 
(PD-L1), Programmed Death receptor 1 (PD-1) and Cytotoxic-T Lymphocyte Antigen 4 
(CTLA 4) inhibitors in urothelial carcinoma focusing our attention on the developing new 
immune-agents and combination strategies with immune-checkpoint inhibitors.   
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